Peptide basics
772 papers, zero human trials: the compounds with a literature and no record
On this page
Publication counts and trial counts measure different things. A paper can be a cell-culture experiment, a mouse study, a review of other papers, or a letter.
Several compounds tracked here have substantial literatures and no registered human trial at all.
MGF has 772 indexed publications over ten years and zero verified human trials. Humanin has 336 and zero. GHRP-6 has 134 and zero.
That combination is genuinely informative: it means the compound is interesting enough to study in a laboratory, and nobody has taken it into a controlled human trial.
This page compares publication counts with registered trial counts for the compounds tracked here. Neither figure says whether a compound works. No dose, schedule or route appears on this page.
The two counts measure different things
A publication count is the number of indexed papers naming a compound in their title or abstract. It includes work in cells, work in animals, reviews that synthesise other people's work, editorials, case reports and letters. All of it is real science and almost none of it involves giving the compound to a person in a controlled setting.1
A registered trial count is the number of studies in which the compound was administered to human participants under a protocol filed in advance. It is a much narrower thing, and a much smaller number.4
The compounds where the gap is widest
- MGF: 772 indexed publications, 0 verified human trials.
- Humanin: 336 indexed publications, 0 verified human trials.
- GHRP-6: 134 indexed publications, 0 verified human trials.
- Semax: 53 indexed publications, 0 verified human trials in English-language registries.
- Hexarelin: 32 indexed publications, 0 verified human trials.234
MGF is the sharpest example because the two numbers are so far apart. Seven hundred and seventy-two papers is a serious body of work by any standard. It sits alongside a registry entry that is completely empty.24
Why this pattern is common and not sinister
Laboratory research is cheaper than a clinical trial by orders of magnitude, and it does not require a sponsor willing to fund development or a regulator willing to allow dosing in humans. Interesting molecules therefore accumulate papers long before anyone attempts a trial, and many never get one.1
For a compound with no patent position or no obvious commercial route, the trial may simply never be worth anyone's money. That is a fact about incentives rather than about the molecule.4
How this is used in marketing
The phrase to watch for is studies show, followed by no identifier. A publication count supports sentences like extensively researched and hundreds of studies, both of which are literally true of MGF and both of which imply something that is not.2
The question that separates the two is simply which studies, in people. A compound with human trials has NCT numbers. A compound with only a literature has citations to laboratory work, and those citations will not mention participants.4
Common questions
Does a big literature make a human trial more likely to succeed?
It makes one more likely to be attempted. Translation rates from laboratory and animal work into successful human trials are low across all of medicine, which is exactly why the trial is required.
Are these paper counts complete?
They are counts of PubMed-indexed publications matching the compound name in title or abstract over ten years. Work published outside indexed journals is not included.
Why do some compounds show zero papers and zero trials?
Usually because the name is too new, too proprietary, or too variable to phrase-match reliably. A zero on both counts should be read as no public record found, not as proof of nothing.
Sources
- RegulatoryPubMed E-utilities — phrase search in title and abstractU.S. National Library of Medicine, 2026www.ncbi.nlm.nih.gov/books/NBK25501/ ↗↩ Back to text
- RegulatoryPubMed search — mechano growth factorU.S. National Library of Medicine, 2026pubmed.ncbi.nlm.nih.gov/?term=%22mechano+growth+factor%22 ↗↩ Back to text
- RegulatoryPubMed search — humaninU.S. National Library of Medicine, 2026pubmed.ncbi.nlm.nih.gov/?term=%22humanin%22 ↗↩ Back to text
- RegulatoryClinicalTrials.gov API v2 — verified interventional recordsU.S. National Library of Medicine, 2026clinicaltrials.gov/data-api/api ↗↩ Back to text